News
-
-
-
COMMUNIQUÉ DE PRESSE
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
Athos Therapeutics announces positive Phase 1 results for ATH-063, an oral small molecule G9A inhibitor for inflammatory bowel disease (IBD), confirming Treg activation and AI2 platform predictions
